A bill adopted by the US Senate is the latest bipartisan move to tighten the grip in the country over companies from China seeking an initial public offering, a step that adds further uncertainty for biotech firms making such plans.
The Senate has passed a bill requiring companies listed in the US to submit an audit by an independent firm every year, a requirement that is likely to be unfulfilled by Chinese companies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?